Related Experiment Video
Updated: Feb 8, 2026
Author Spotlight: Emerging Technologies and Advanced Tools for Decoding Metabolomics Data Analysis
Published on: November 10, 2023
The ERBB network facilitates KRAS-driven lung tumorigenesis
Björn Kruspig1, Tiziana Monteverde1, Sarah Neidler1
1Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1BD, UK.
Abstract:
KRAS is the most frequently mutated driver oncogene in human adenocarcinoma of the lung. There are presently no clinically proven strategies for treatment of KRAS-driven lung cancer. Activating mutations in KRAS are thought to confer independence from upstream signaling; however, recent data suggest that this independence may not be absolute. We show that initiation and progression of KRAS-driven lung tumors require input from ERBB family receptor tyrosine kinases (RTKs): Multiple ERBB RTKs are expressed and active from the earliest stages of KRAS-driven lung tumor development, and treatment with a multi-ERBB inhibitor suppresses formation of KRASG12D-driven lung tumors. We present evidence that ERBB activity amplifies signaling through the core RAS pathway, supporting proliferation of KRAS-mutant tumor cells in culture and progression to invasive disease in vivo. Brief pharmacological inhibition of the ERBB network enhances the therapeutic benefit of MEK (mitogen-activated protein kinase kinase) inhibition in an autochthonous tumor setting. Our data suggest that lung cancer patients with KRAS-driven disease may benefit from inclusion of multi-ERBB inhibitors in rationally designed treatment strategies.
Insights
Targeting ERBB receptor tyrosine kinases (RTKs) is crucial for treating KRAS-driven lung cancer. Inhibiting ERBB RTKs suppresses tumor growth and enhances other cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- KRAS is a key oncogene in lung adenocarcinoma, but effective treatments are lacking.
- KRAS mutations are thought to grant cancer cells independence from upstream signaling pathways.
Purpose of the Study:
- To investigate the role of ERBB receptor tyrosine kinases (RTKs) in KRAS-driven lung cancer.
- To explore potential therapeutic strategies targeting ERBB RTKs in this cancer type.
Main Methods:
- Analyzing ERBB RTK expression and activity in KRAS-driven lung tumors.
- Utilizing multi-ERBB inhibitors to suppress tumor formation.
- Investigating the impact of ERBB inhibition on RAS pathway signaling.
- Evaluating the combination therapy of ERBB inhibition with MEK inhibitors.
Main Results:
- ERBB RTKs are active early in KRAS-driven lung tumor development.
- Multi-ERBB inhibition suppressed the formation of KRASG12D-driven lung tumors.
- ERBB activity amplifies RAS pathway signaling, promoting tumor cell proliferation and progression.
- Combined ERBB and MEK inhibition showed enhanced therapeutic benefits in preclinical models.
Conclusions:
- KRAS-driven lung cancer initiation and progression depend on ERBB RTK signaling.
- Targeting ERBB RTKs, potentially with multi-ERBB inhibitors, is a promising therapeutic strategy.
- Combination therapies involving ERBB inhibitors may improve outcomes for patients with KRAS-driven lung cancer.
More Related Videos
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
05:56Author Spotlight: Enhancing Diagnostic Strategies and Biomarker Development for Comprehensive Lung Function Analysis
Published on: August 9, 2024
Related Concept Videos
01:19Facilitated Transport
01:19Facilitated Transport
01:04Social Facilitation
01:16Facilitated Diffusion
In this process, substrates such as organic compounds and ions interact with a transporter on one side, triggering conformational changes in proteins that enable...
02:26Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
02:26Protein Networks